• Profile
Close

Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: An open-label phase IB trial

Journal of Clinical Oncology Aug 16, 2019

Sheng X, Yan X, Chi Z, et al. - Among 33 patients with advanced melanoma, including those with chemotherapy-naïve mucosal melanomas (88%), researchers tested toripalimab in combination with axitinib, focusing on the safety and preliminary effectiveness of this treatment option, in this single-center, phase IB trial. In this dose-escalation and cohort-expansion study, the patients were administered toripalimab at 1 or 3 mg/kg via intravenous infusion every 2 weeks, in combination with axitinib 5 mg orally twice a day. In Asian patients with treatment-naïve metastatic mucosal melanoma, tolerability and promising antitumor activity of the combination of toripalimab plus axitinib were evident in this study. To be used as a standard of care, validation of this combination therapy in a randomized phase 3 trial involving a non-Asian population is necessary. Diarrhea, proteinuria, hand and foot syndrome, fatigue, AST or ALT elevation, hypertension, hypo- or hyperthyroidism, and rash were the most common treatment-related adverse events and most were mild (grade 1 or 2).

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay